148 related articles for article (PubMed ID: 15577628)
1. Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States.
Pinkerton SD; Martin JN; Roland ME; Katz MH; Coates TJ; Kahn JO
AIDS; 2004 Oct; 18(15):2065-73. PubMed ID: 15577628
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus.
Pinkerton SD; Martin JN; Roland ME; Katz MH; Coates TJ; Kahn JO
Arch Intern Med; 2004 Jan; 164(1):46-54. PubMed ID: 14718321
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of post-exposure prophylaxis following sexual exposure to HIV.
Pinkerton SD; Holtgrave DR; Bloom FR
AIDS; 1998 Jun; 12(9):1067-78. PubMed ID: 9662204
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
Pinkerton SD; Holtgrave DR; Pinkerton HJ
Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of HIV post-exposure prophylaxis in France.
Herida M; Larsen C; Lot F; Laporte A; Desenclos JC; Hamers FF
AIDS; 2006 Aug; 20(13):1753-61. PubMed ID: 16931940
[TBL] [Abstract][Full Text] [Related]
6. Non-occupational postexposure prophylaxis for HIV: a systematic review.
Bryant J; Baxter L; Hird S
Health Technol Assess; 2009 Feb; 13(14):iii, ix-x, 1-60. PubMed ID: 19236820
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of human immunodeficiency virus postexposure prophylaxis for healthcare workers.
Scheid DC; Hamm RM; Stevens KW
Pharmacoeconomics; 2000 Oct; 18(4):355-68. PubMed ID: 15344304
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of preventing AIDS-related opportunistic infections.
Freedberg KA; Scharfstein JA; Seage GR; Losina E; Weinstein MC; Craven DE; Paltiel AD
JAMA; 1998 Jan; 279(2):130-6. PubMed ID: 9440663
[TBL] [Abstract][Full Text] [Related]
9. Postexposure prophylaxis for HIV after sexual assault.
Myles JE; Hirozawa A; Katz MH; Kimmerling R; Bamberger JD
JAMA; 2000 Sep; 284(12):1516-8. PubMed ID: 11000643
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study.
Kahn JO; Martin JN; Roland ME; Bamberger JD; Chesney M; Chambers D; Franses K; Coates TJ; Katz MH
J Infect Dis; 2001 Mar; 183(5):707-14. PubMed ID: 11181146
[TBL] [Abstract][Full Text] [Related]
11. Human immunodeficiency virus postexposure prophylaxis for adolescents and children.
Merchant RC; Keshavarz R
Pediatrics; 2001 Aug; 108(2):E38. PubMed ID: 11483848
[TBL] [Abstract][Full Text] [Related]
12. HIV infection and risk, prevention, and testing behaviors among injecting drug users -- National HIV Behavioral Surveillance System, 20 U.S. cities, 2009.
Broz D; Wejnert C; Pham HT; DiNenno E; Heffelfinger JD; Cribbin M; Krishna N; Teshale EH; Paz-Bailey G;
MMWR Surveill Summ; 2014 Jul; 63(6):1-51. PubMed ID: 24990587
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of the WINGS intervention: a program to prevent HIV and sexually transmitted diseases among high-risk urban women.
Chesson HW; Greenberg JB; Hennessy M
BMC Infect Dis; 2002 Oct; 2():24. PubMed ID: 12377102
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of a community-level HIV risk reduction intervention for women living in low-income housing developments.
Johnson-Masotti AP; Pinkerton SD; Sikkema KJ; Kelly JA; Wagstaff DA
J Prim Prev; 2005 Jul; 26(4):345-62. PubMed ID: 15995803
[TBL] [Abstract][Full Text] [Related]
15. Seroconversion following nonoccupational postexposure prophylaxis against HIV.
Roland ME; Neilands TB; Krone MR; Katz MH; Franses K; Grant RM; Busch MP; Hecht FM; Shacklett BL; Kahn JO; Bamberger JD; Coates TJ; Chesney MA; Martin JN
Clin Infect Dis; 2005 Nov; 41(10):1507-13. PubMed ID: 16231265
[TBL] [Abstract][Full Text] [Related]
16. Cost-utility of HIV Testing Programs Among Men Who Have Sex with Men in the United States.
Zulliger R; Maulsby C; Solomon L; Baytop C; Orr A; Nasrullah M; Shouse L; DiNenno E; Holtgrave D
AIDS Behav; 2017 Mar; 21(3):619-625. PubMed ID: 27624729
[TBL] [Abstract][Full Text] [Related]
17. Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis.
Hugo JM; Stall RD; Rebe K; Egan JE; De Swardt G; Struthers H; McIntyre JA
AIDS Behav; 2016 Dec; 20(Suppl 3):357-364. PubMed ID: 27631366
[TBL] [Abstract][Full Text] [Related]
18. A cost-effectiveness analysis of HIV preexposure prophylaxis for men who have sex with men in Australia.
Schneider K; Gray RT; Wilson DP
Clin Infect Dis; 2014 Apr; 58(7):1027-34. PubMed ID: 24385445
[TBL] [Abstract][Full Text] [Related]
19. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men.
Goldie SJ; Kuntz KM; Weinstein MC; Freedberg KA; Welton ML; Palefsky JM
JAMA; 1999 May; 281(19):1822-9. PubMed ID: 10340370
[TBL] [Abstract][Full Text] [Related]
20. Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior.
Martin JN; Roland ME; Neilands TB; Krone MR; Bamberger JD; Kohn RP; Chesney MA; Franses K; Kahn JO; Coates TJ; Katz MH
AIDS; 2004 Mar; 18(5):787-92. PubMed ID: 15075514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
